Docoh
Loading...

24 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
personnel incentive, recruiting and retention objectives, making it more difficult to meet these objectives. This ultimately may undermine our success … . The alternative to using equity for retention and incentive purposes would be to significantly increase cash compensation. We do not believe increasing cash
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
. Change of Control. To the extent a participant has an employment, retention, change of control, severance, or similar agreement with us or any
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
otherwise reserved or available under the Omnibus Plan. Change of Control. To the extent a participant has an employment, retention, change of control
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
. To the extent a participant has an employment, retention, change of control, severance, or similar agreement with us or any of our affiliates
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
. To the extent a participant has an employment, retention, change of control, severance, or similar agreement with us or any of our affiliates
S-1/A
EX-10.5
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
in a Participant’s employment, retention, change of control, severance, Award agreement or similar agreement with the Company or any Affiliate … given in a Participant’s employment, retention, change of control, severance, Award agreement or similar agreement with the Company or any Affiliate
S-1/A
EX-10.13
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
retention requirements by a Party leads to the imposition of withholding Tax liability or VAT on the other Party that would not have been imposed
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
retention requirements by a Party leads to the imposition of withholding Tax liability or VAT on the other Party that would not have been imposed
DEF 14A
PCSA Processa Pharmaceuticals Inc
26 Apr 19
Definitive proxy
5:02pm
sales; cross/integrated sales; customer engagement; internal revenue growth; client retention; the achievement of research, production, or regulatory … the Plan. Change of Control.To the extent a participant has an employment, retention, change of control, severance, or similar agreement with us
10-K
2016 FY
PCSA Processa Pharmaceuticals Inc
24 Sep 17
Annual report
8:00pm
the retention of the independent auditors for the performance of all audit and non-audit services that are not prohibited and the fees
10-K
2015 FY
PCSA Processa Pharmaceuticals Inc
18 Jun 17
Annual report
8:00pm
The Audit Committee reviewed and approved in advance the retention of the independent auditors for the performance of all audit and non-audit services
10-K
2014 FY
PCSA Processa Pharmaceuticals Inc
13 Apr 15
Annual report
8:00pm
-Approval The Audit Committee reviews and approves in advance the retention of the independent auditors for the performance of all audit and non-audit
8-K
EX-99.5
PCSA Processa Pharmaceuticals Inc
19 Feb 15
Senior Secured Loan Agreement
7:00pm
a conditional sale agreement, capital lease or other title retention agreement, or any agreement to provide any of the foregoing, and the filing of any financing
10-K
2013 FY
PCSA Processa Pharmaceuticals Inc
26 Mar 14
Annual report
8:00pm
and commercialization of our preservation and repair equipment involves many difficulties, including: · retention and hiring of appropriate operational, research … -Approval The Audit Committee reviews and approves in advance the retention of the independent auditors for the performance of all audit and non-audit
424B3
PCSA Processa Pharmaceuticals Inc
5 Jun 13
Prospectus supplement
8:00pm
and commercialization of our preservation and repair equipment involves many difficulties, including: retention and hiring of appropriate operational
S-1/A
EX-10.15
PCSA Processa Pharmaceuticals Inc
22 May 13
IPO registration (amended)
8:00pm
, capital lease or other title retention agreement, or any agreement to provide any of the foregoing, and the filing of any financing statement
S-1/A
PCSA Processa Pharmaceuticals Inc
22 May 13
IPO registration (amended)
8:00pm
many difficulties, including: retention and hiring of appropriate operational, research and development personnel; determining the products
S-1/A
PCSA Processa Pharmaceuticals Inc
14 May 13
IPO registration (amended)
8:00pm
: retention and hiring of appropriate operational, research and development personnel; determining the products’ technical specifications; successful
S-1/A
PCSA Processa Pharmaceuticals Inc
10 Apr 13
IPO registration (amended)
8:00pm
and commercialization of our preservation and repair equipment involves many difficulties, including: retention and hiring of appropriate operational
S-1/A
PCSA Processa Pharmaceuticals Inc
13 Mar 13
IPO registration (amended)
8:00pm
and repair equipment involves many difficulties, including: retention and hiring of appropriate operational, research and development personnel